secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-031835
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Q2 net sales up 69% to $4.2M; operating loss improves 81% to $1.4M
-------------------------------------------------------------------------

- Net product sales $4.2M (+69% YoY); net income $1.3M ($0.02/share) vs net loss $8.6M ($5.43) in prior year.
- Operating expenses down 43% to $5.5M; operating loss improved 81% to $1.4M.
- Acquired global rights to SOLOSEC (secnidazole) for bacterial vaginosis and trichomoniasis.
- Licensed Phexxi commercial rights in Middle East to Pharma 1 Drug Store; partnered with Hello Alpha.
- Received $2.0M from Aditxt related to merger; targeting late 2024 close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224031835/0001493152-24-031835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224031835/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer